The 80th Annual Meeting of the Japanese Society of Hematology

Presentation information

Print

Morning Seminar

MS2-6

Treatment Strategy for Lenalidomide Refractory Multiple Myeloma

Sat. Oct 13, 2018 8:00 AM - 8:45 AM No.6 (Osaka International Convention Center, 10F 1003)

Chair: Tadao Ishida (Department of Hematology, Japanese Red Cross Medical Center, Tokyo, Japan)

Sponsor: Celgene K.K.

[MS2-6] Treatment Strategy for Lenalidomide Refractory Multiple Myeloma

Paul G Richardson (Harvard Medical School/Dana-Farber Cancer Institute, Boston, M.A.(USA))